Clinical trials: SARSCoV2 Convalescent Plasma
COVID-19
Efficacy and Safety of Convalescent Plasma in Treating COVID-19 Hospitalized Patients
This is a Phase II study. This research study is being conducted to use convalescent donor plasma in seriously ill patients who have COVID-19.
- Trial name
- NCT04354831
- Testing
- anti-SARS-CoV-2 convalescent plasma
- Where
- United States
- Volunteers
- 131 people
- Sponsor
- Medical College of Wisconsin
COVID-19
Safety in Convalescent Plasma Transfusion to COVID-19
There is currently no specific vaccine or treatment to treat critically ill patients with COVID-19. Different therapies are still under investigation and are use in different health institutions, however, a significant proportion…
- Trial name
- NCT04333355
- Testing
- Convalescent Plasma
- Where
- Mexico
- Volunteers
- 12 people
- Sponsor
- TecSalud Investigación Clínica
COVID-19
Convalescent Plasma as Treatment for Subjects With Early COVID-19 Infection
This is a phase II randomized study of convalescent plasma for the treatment of non-immune individuals with COVID-19 infection at high risk of complications.
- Trial name
- NCT04456413
- Testing
- Convalescent Plasma, Best Supportive Care
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Hackensack Meridian Health
Covid19, Coronavirus Infection
TranSfUsion of coNvalescent plAsma for the Early Treatment of pneuMonIa in COVID-19 Patients
This is a multicenter open-label randomized study for the early treatment of pneumonia due to SARS-COV2 with transfusion of convalescent plasma.
- Conditions
- Covid19, Coronavirus Infection, Pneumonia, Viral
- Trial name
- NCT04716556
- Testing
- Convalescent plasma
- Where
- 48 sites in Italy
- Volunteers
- 474 people
- Sponsor
- Istituto Superiore di Sanità
Covid19, Immuno-Deficiency
Preemptive Use of Convalescent Plasma for High-risk Patients With COVID-19
Convalescent plasma therapy has been recognized as safe and plasma transfusion is routinely used in clinical practice. A recent study showed that early administration of convalescent plasma can decrease the risk of complications…
- Conditions
- Covid19, Immuno-Deficiency, Old Age; Debility
- Trial name
- NCT04836260
- Testing
- SARS-CoV-2 convalescent plasma
- Where
- 4 sites in Switzerland
- Volunteers
- 100 people
- Sponsor
- University Hospital, Geneva
Coronavirus Disease 2019 (COVID-19)
Observational Study of Convalescent Plasma for Treatment of Veterans With COVID-19
The purpose of this study is to assess whether convalescent plasma therapy is associated with reduced 30-day all-cause mortality in a population of Veteran inpatients with non-severe coronavirus disease 2019 (COVID-19).
- Trial name
- NCT04545047
- Testing
- COVID-19 convalescent plasma
- Where
- 2 sites in United States
- Volunteers
- 5,044 people
- Sponsor
- VA Office of Research and Development
COVID-19
COVID-19 Convalescent Plasma for the Treatment of Hospitalized Patients With Pneumonia Caused by SARS-CoV-2.
The purpose of this study is to see if this plasma can be safely used in humans with COVID-19 and to see if it improves patients' health as compared to not using it in patients with pneumonia caused by SARS-CoV-2.
- Trial name
- NCT04397757
- Testing
- COVID-19 Convalescent Plasma
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- University of Pennsylvania
COVID19
Clinical Study for Efficacy of Anti-Corona VS2 Immunoglobulins Prepared From COVID19 Convalescent Plasma Prepared by VIPS Mini-Pool IVIG Medical Devices in Prevention of SARS-CoV-2 Infection in High Risk Groups as Well as Treatment of Early Cases of COVID19 Patients
Preparation of safe purified hyper immunoglobulins containing anti-Corona VS2 immunoglobulins from plasma collected from COVID19 convalescent patients to be used to: 1.
- Trial name
- NCT04383548
- Testing
- hyper immunoglobulins containing anti-Corona VS2 immunoglobulin
- Volunteers
- 100 people
- Sponsor
- Assiut University
Covid19, Mechanical Ventilation Complication
Efficacy of CONvalescent Plasma in Patients With COVID-19 Treated With Mechanical Ventilation
The principal objective of the CONFIDENT trial is to assess the efficacy of two units (400-500 mL in total) of convalescent plasma, as compared to Standard of Care (SoC), to reduce day-28 mortality in patients with SARS-CoV-2…
- Conditions
- Covid19, Mechanical Ventilation Complication, Corona Virus Infection, Respiratory Failure
- Trial name
- CONFIDENT (NCT04558476)
- Testing
- Convalescent Plasma, Standard of Care
- Where
- 17 sites in Belgium
- Volunteers
- 475 people
- Sponsor
- University of Liege
COVID-19 Convalescent Plasma Treatment
Covid-19 Convalescent Plasma and Monoclonal Antibodies Treatment of Immunocompromised Patients
Data on the use of convalescent plasma in the treatment of covid-19 are scarce: the results of randomized studies involving mainly immunocompetent patients are disappointing, while case series or retrospective data on more…
- Trial name
- Covid-IC (NCT05905380)
- Where
- France
- Volunteers
- 200 people
- Sponsor
- University Hospital, Strasbourg, France
SARS-CoV-2 Infection, Safety and Efficacy
Plasma for Early Treatment in Non-hospitalised Mild or Moderate COVID-19 Patients
This is a prospective, randomized (1:1), double blind study of Convalescent anti-SARS-CoV-2 MBT Plasma (also known as convalescent plasma) plus standard medical treatment (SMT) versus placebo plus SMT in mild or moderate COVID-19…
- Trial name
- NCT04621123
- Testing
- Convalescent anti-SARS-CoV-2 MBT plasma, Control Group
- Where
- 4 sites in Spain
- Volunteers
- 384 people
- Sponsor
- Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia
Covid-19, Sars-CoV2
Convalescent Plasma in ICU Patients With COVID-19-induced Respiratory Failure
This study will assess the feasibility of administering multiple doses of convalescent plasma (from people who have recovered form SARS-CoV-2) to Covid-19 positive patients in the Intensive Care Unit receiving mechanical…
- Trial name
- NCT04353206
- Testing
- Multiple Doses of Anti-SARS-CoV-2 convalescent plasma
- Where
- 2 sites in United States
- Volunteers
- 6 people
- Sponsor
- Noah Merin
Coronavirus
Anti-SARS-CoV-2 Inactivated Convalescent Plasma in the Treatment of COVID-19
There is still no effective antiviral drugs and vaccines against SARS-CoV-2 yet now. This is an obsevational study, the investigators collected the clinical information and clinical outcomes of the COVID-19 patients using…
- Trial name
- NCT04292340
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Shanghai Public Health Clinical Center
COVID-19, Coronavirus
CONTAIN COVID-19: Convalescent Plasma to Limit COVID-19 Complications in Hospitalized Patients
This is a randomized, blinded phase 2 trial that will assess the efficacy and safety of anti-SARS-CoV-2 convalescent plasma in hospitalized patients with acute respiratory symptoms requiring oxygen supplementation.
- Conditions
- COVID-19, Coronavirus, Coronavirus Infection
- Trial name
- NCT04364737
- Testing
- Convalescent Plasma, Saline solution
- Where
- 9 sites in United States
- Volunteers
- 941 people
- Sponsor
- NYU Langone Health
Covid19
Convalescent Plasma in the Early Treatment of High-Risk Patients With SARS-CoV-2 (COVID-19) Infection
This study proposes to evaluate the therapeutic efficacy, immunologic effects and normalization of laboratory parameters for patients at high risk for mortality when infected by SARS-CoV-2 (COVID-19) when administered one unit…
- Trial name
- NCT04513158
- Testing
- Convalescent Plasma
- Where
- 4 sites in United States
- Volunteers
- 2 people
- Sponsor
- Joseph M. Flynn, D.O., MPH
SARS-CoV-2 Infection, COVID-19 Infection
COVID-19 Convalescent Plasma Therapy
This study is an open-label trial in which hospitalized patients with risk factors of severe coronavirus disease 2019 [COVID-19] will be receive treatment with convalescent plasma (≤ 15 days from symptoms start).
- Trial name
- TPCC (NCT04747158)
- Testing
- Convalescent plasma
- Where
- Paraguay
- Volunteers
- 350 people
- Sponsor
- Universidad Nacional de Asunción
COVID-19
Convalescent Plasma for Treatment of COVID-19: An Exploratory Dose Identifying Study
Convalescent plasma has been shown to be safe and effective for treatment of several diseases. Preliminary data indicates that it is safe and effective for treatment of COVID.
- Trial name
- NCT04384497
- Testing
- SARS-CoV-2 convalescent plasma
- Where
- 2 sites in Sweden
- Volunteers
- 10 people
- Sponsor
- Joakim Dillner
COVID-19
Efficacy of Convalescent Plasma Therapy in the Early Care of COVID-19 Patients.
COVID-19 (Corona Virus Disease 2019) hospitalized patients evolution is marked by the risk of worsening of the respiratory system during the second week of the disease.
- Trial name
- PLASCOSSA (NCT04372979)
- Testing
- Transfusion of SARS-CoV-2 Convalescent Plasma., Transfusion of standard Plasma.
- Where
- 4 sites in France
- Volunteers
- 18 people
- Sponsor
- Direction Centrale du Service de Santé des Armées
COVID-19
Safety and Efficacy of Convalescent Plasma Transfusion for Patients With COVID-19
This is a multicenter double blinded study to evaluate the efficacy and safety of convalescent plasma from COVID-19 recovered individuals to treat hospitalized patients with severe COVID-19 disease.
- Trial name
- EPCOvid-1 (NCT04388410)
- Testing
- convalescent plasma
- Where
- Mexico
- Volunteers
- 410 people
- Sponsor
- Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
COVID-19
A Study to Evaluate Safety and Efficacy of Convalescent Methylene Blue Treated (MBT) Plasma From Donors Recovered From Coronavirus Disease 2019 (COVID-19)
The purpose of the study is to determine if Convalescent anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Methylene Blue Treated (MBT) plasma plus Standard Medical Treatment (SMT) can reduce all-cause mortality…
- Trial name
- NCT04547127
- Testing
- Convalescent anti-SARS-CoV-2 MBT Plasma, Standard Medical Treatment
- Where
- 12 sites in Spain
- Volunteers
- 200 people
- Sponsor
- Instituto Grifols, S.A.